.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Farmers Insurance
McKesson
Harvard Business School
Queensland Health
Cantor Fitzgerald
Merck
Chinese Patent Office
QuintilesIMS

Generated: December 14, 2017

DrugPatentWatch Database Preview

ADALAT CC Drug Profile

« Back to Dashboard

When do Adalat Cc patents expire, and what generic alternatives are available?

Adalat Cc is a drug marketed by Alvogen and is included in one NDA.

The generic ingredient in ADALAT CC is nifedipine. There are thirty-nine drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the nifedipine profile page.
Drug patent expirations by year for ADALAT CC

Pharmacology for ADALAT CC

Medical Subject Heading (MeSH) Categories for ADALAT CC

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
AlvogenADALAT CCnifedipineTABLET, EXTENDED RELEASE;ORAL020198-001Apr 21, 1993AB1RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
AlvogenADALAT CCnifedipineTABLET, EXTENDED RELEASE;ORAL020198-002Apr 21, 1993AB1RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AlvogenADALAT CCnifedipineTABLET, EXTENDED RELEASE;ORAL020198-003Apr 21, 1993AB1RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ADALAT CC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
AlvogenADALAT CCnifedipineTABLET, EXTENDED RELEASE;ORAL020198-001Apr 21, 1993► Subscribe► Subscribe
AlvogenADALAT CCnifedipineTABLET, EXTENDED RELEASE;ORAL020198-003Apr 21, 1993► Subscribe► Subscribe
AlvogenADALAT CCnifedipineTABLET, EXTENDED RELEASE;ORAL020198-002Apr 21, 1993► Subscribe► Subscribe
AlvogenADALAT CCnifedipineTABLET, EXTENDED RELEASE;ORAL020198-003Apr 21, 1993► Subscribe► Subscribe
AlvogenADALAT CCnifedipineTABLET, EXTENDED RELEASE;ORAL020198-002Apr 21, 1993► Subscribe► Subscribe
AlvogenADALAT CCnifedipineTABLET, EXTENDED RELEASE;ORAL020198-001Apr 21, 1993► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Argus Health
Medtronic
McKinsey
Julphar
Baxter
Novartis
Express Scripts
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot